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ABSTRACT
Vasopressin binding to the V2 receptor in renal principal cells leads to activation of protein kinase A,
phosphorylation of aquaporin 2 (AQP2) at Ser256, and the translocation of AQP2 to the apical membrane,
resulting in concentration of the urine. In contrast, phorbol ester–induced activation of protein kinase C
pathway leads to ubiquitination of AQP2 at Lys270 and its internalization to multivesicular bodies, where it
is targeted for lysosomal degradation or stored for recycling. Because little is known about the regulation of
AQP2 trafficking, we used the carboxy-terminal tail of constitutively nonphosphorylated AQP2 (S256A) as a
bait for interacting proteins in a yeast two-hybrid assay. We isolated lysosomal trafficking regulator–
interacting protein 5 (LIP5) and found that LIP5 interactedwith the proximal carboxy-terminal tail (L230-D243)
of AQP2 in vitro but not with AQP3 or AQP4, which are also expressed in principal cells. Immunohistochem-
istry revealed that LIP5 co-localized with AQP2 in principal cells. LIP5 binding occurred independent of the
state of Ser256 phosphorylation or Lys270 ubiquitination. LIP5 has been shown to facilitate degradation of
the EGF receptor; here, LIP5 seemed to bind this receptor. Knockdown of LIP5 in mouse renal cells
(mpkCCD) reduced the phorbol ester–induced degradation of AQP2 approximately two-fold. In summary,
LIP5 binds cargo proteins and, considering the role of LIP5 in protein sorting to multivesicular bodies, plays
a role in the degradation of AQP2, possibly by reducing the formation of late endosomes.
J Am Soc Nephrol 20: 990–1001, 2009. doi: 10.1681/ASN.2008060648
Tight regulation of the translocation of aquaporin 2
(AQP2) water channels to and from the apical
membrane of renal collecting duct cells by the anti-
diuretic hormone arginine vasopressin (AVP) is
fundamental for water homeostasis. Upon hyper-
natremia or hypovolemia, binding of AVP to its
type 2 receptor (V2R) increases intracellular cal-
cium and cAMP concentrations, which activate and
tether protein kinase A (PKA) to AQP2-containing
vesicles, resulting in phosphorylation of AQP2 and
other proteins.1–7 Consequently, these vesicles dock
and fuse with the apicalmembrane, rendering prin-
cipal cells water permeable.
Regulated translocation of AQP2 to and from
the apical membrane suggests the existence of pro-
teins interacting with cytosolic segments of AQP2.
Only the amino-terminal and carboxyl-terminal
tails (N- and C-tails, respectively) of AQP2 extend
well into the cytosol, and the C-tail of AQP2 has
been shown to have an important role in its apical
sorting: First, Ser256 in the AQP2 C-tail is phos-
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phorylated in vivo by AVP stimulation, and studies in both cell
and animal models revealed that this phosphorylation event is
essential for AQP2 translocation to the plasma membrane.8–13
Second, all AQP2 mutants encoded in families with a domi-
nant inheritance of nephrogenic diabetes insipidus (NDI), a
disease in which the kidney is unable to concentrate urine in
response to AVP, are missorted as a result of mutations in the
C-tail.12,14–19 In addition, the AQP2 C-tail is mono-ubiquiti-
nated at Lys270 upon AVP removal or PKC activation, which
enhances endocytosis and degradation of AQP2.20
So far, the Rap1 GTPase-activating protein Spa1, heat-
shockprotein70, andMyelinandLymphocyteAssociatedProtein
(MAL) are the only proteins known to bind the AQP2 C-tail,
potentially playing physiologic roles in AQP2 trafficking21–23;
therefore, to gain more insight in the proteins and mechanisms
involved in the regulation of AQP2, we used yeast two-hybrid
assays to screen a mouse kidney cDNA library for proteins inter-
acting with the C-tail of AQP2.We found the lysosomal traffick-
ing regulator (LYST) interactingprotein5 (LIP5; Swiss-Prot entry
Q9CR26; corresponding gene name DRG-1) to interact specifi-
cally with AQP2. Interestingly, LIP5 is reported to function in
multivesicular body (MVB) formation,24 although a direct inter-
action of LIP5withMVB cargo proteins has never been reported.
Subsequent analyses revealed the LIP5-binding region within
AQP2 and the role of LIP5 in AQP2 regulation.
RESULTS
Screening for AQP2-Interacting Proteins
To isolate proteins involved in AQP2 regulation, we trans-
fected yeast cells expressing (for clarity, expression refers to
protein expression unless indicated otherwise) a fusion protein
of LexA and the C-tail of AQP2-S256A with a mouse kidney
cDNA library, grown under selective conditions and screened
for -galactosidase activity. Approximately 3.85  106 colo-
nies were screened. Of the 22 initial positive clones, six re-
mained positive after rescreening in combination with the
AQP2-S256A bait construct but not with the empty bait plas-
mid. Sequence analysis of the positive clones revealed that all
six clones encoded the same protein showing 100% identity to
a mouse RIKEN cDNA library clone annotatedMus musculus
Vps20-associated 1 homolog (Saccharomyces cerevisiae; Entrez
GeneID 66201), encoding the mouse orthologue of human
LIP5. A schematic representation and primary sequence of
LIP5 are depicted in Supplemental Figure 1. Among the six
positive clones, four different positions for LexA-fusion were
observed, all of them within the first eight N-terminal LIP5
residues, indicating that the product of several independent
clones interacted with the AQP2 C-tail.
Site and Specificity of the AQP2–LIP5 Interaction
To allow further characterization of the role of LIP5 in AQP2
binding and regulation, we generated antibodies directed
against full-length LIP5. Immunohistochemical/cytochemical
and immunoblot data (Supplemental Figure 2) and the immu-
noblot data from the LIP5 shRNA experiment reveal the spec-
ificity of our LIP5 antibodies.
To identify the LIP5-binding region in AQP2, we conducted
yeast two-hybrid assays with truncated AQP2 C-tails. -Galacto-
sidase assays revealed that AQP2C-tails truncated atQ263, R252,
andD243were still able to interactwithLIP5,whereas interaction
was lostwithAQP2 truncated at L230 (Figure 1A), indicating that
region 230 to 243 of AQP2 is essential for LIP5 binding.
In the kidney, AQP2, AQP3, and AQP4 are expressed in the
same cells.25,26 For investigation of the specificity of the LIP5–
AQP2 interaction, LexA-AQP C-tail fusion proteins of AQP2,
AQP3, and AQP4 were expressed in yeast and tested for inter-
action with LIP5. -Galactosidase assays revealed that LIP5
interacted with the C-tail of wt-AQP2 but not with the C-tails
of AQP3 (M264-I292) orAQP4 (V251-V323; Figure 1A). Yeast
cells transfected with bait and empty pACT2 constructs revealed
no staining (Figure 1A). Immunoblot analysis of the yeast cells
confirmed expression of the bait and prey proteins (data not
shown). For confirmation and further testing of whether LIP5
directly interacts with the AQP2 tail or requires additional pro-
teins, 35S-methionine/cysteine-labeled LIP5 was synthesized in
vitro and incubated with glutathione S-transferase (GST), GST-
AQP2, or GST-AQP4 coupled to glutathione Sepharose beads.
Autoradiography of the eluted proteins showed that LIP5, run-
ning at approximately 42 kD, directly interacts with GST-AQP2
but, again, not with GST-AQP4 or GST (Figure 1B).
To investigate whether renal LIP5 would specifically inter-
act with the AQP2 tail, we incubated dog kidney cytosol with
GST, GST-AQP2, or GST-AQP4 coupled to glutathione
Sepharose beads. LIP5 immunoblotting of the isolated inter-
acting proteins showed a renal protein of approximately 42 kD
specifically interacting with GST-AQP2 and not with GST or
GST-AQP4 (Figure 1C). These results thus showed that LIP5
binding to the C-tail of AQP2 was specific in relation to the
C-tails of AQP3 and AQP4.
LIP5 Interaction with the EGF Receptor
Our data reveal AQP2 as the first cargo protein identified to
interact with LIP5; however, LIP5 has been reported to facili-
tate EGF receptor (EGFR) degradation and might therefore
also interact with EGFR.24 For testing this, EGFR and Xpress-
tagged LIP5 were coexpressed in HEK293 cells. After EGFR
immunoprecipitation, immunoblotting for the Xpress-tag in-
deed demonstrated that tagged LIP5 co-precipitated with
EGFR (in duplicate; Figure 1D, lanes 1 and 2), indicating that
LIP5 interacts with EGFR. Note that immunoblotting for LIP5
of the cell lysates shows endogenous LIP5 of approximately 42
kD, besides a strong and weak band of Xpress-tagged LIP5.
Our data thus reveal that, besides AQP2, the cargo protein
EGFR interacts with LIP5.
LIP5 Expression in the Kidney
For LIP5 to have a role in the regulation of AQP2 in vivo, it
needs to be present in renal principal cells.We performed LIP5
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in situ hybridization and AQP2 immunohistochemistry on al-
ternating mouse kidney sections. Microscopic analysis re-
vealed that renal principal cells (positive for AQP2; Figure 2A,
2 and 4) indeed also contain LIP5mRNA (Figure 2A, 1 and 3).
Besides these cells, LIP5 mRNA was detected in epithelial cells
of other renal tubules and collecting duct cells. A sense probe of
LIP5 cRNA, which was taken along as a negative control, re-
vealed no staining (Figure 2A, 5).
Next, AQP2 and LIP5 co-localization was determined. Im-
munohistochemistry for AQP2 and LIP5 onmouse kidney sec-
tions and confocal laser scanning microscopy revealed that
AQP2 co-localizes with LIP5 in the apical region of renal prin-
cipal cells (Figure 2B). Interestingly, in AQP2-negative tubules
(arrows in Figure 2B) and intercalating cells (asterisks in Figure
2B), which are the AQP2-negative cells of collecting ducts,
LIP5 showed a punctuate staining, suggesting a vesicular local-
ization of LIP5 in these cells.
Effect of Physiologic Modification in the AQP2 C-Tail
on Its Interaction with LIP5
In vivo, redistribution of AQP2 from intracellular vesicles to
the apical membrane coincides with phosphorylation of AQP2
at Ser256.10,11 Subsequent studies in MDCK cells showed that
phosphorylation at Ser256 is essential and sufficient for apical
membrane localization of AQP2, because AQP2-S256A, which
mimics nonphosphorylated AQP2, is localized in intracellular
vesicles, whereas AQP2-S256D, mimicking phosphorylated
AQP2, is localized in the apical membrane.8 Also, AQP2 mu-
tants in dominantNDIhavemissense or frame-shiftmutations
in the C-tail, one of which is AQP2-E258K.15,16 For determi-
nation of whether LIP5 binding to the AQP2C-tail depends on
the AQP2 phosphorylation state and whether binding is lost
with AQP2 mutants in dominant NDI, the C-tails of AQP2-
S256A, AQP2-S256D, and AQP2-E258K were expressed with
LIP5 in yeast and tested for interaction.-Galactosidase assays
revealed a positive signal for the S256A, S256D, and E258K
C-tails (Figure 1A), suggesting that LIP5 binding is independent
of the AQP2 phosphorylation state and is maintained in the
AQP2-E258K mutant. Using HEK293 cells, transiently-express-
ing AQP2-S256A or AQP2-S256D, co-immunoprecipitation as-
says confirmed that interactionofLIP5withAQP2 is independent
of AQP2 phosphorylation state (Figure 3A).
Besides phosphorylation, AQP2 is subject to mono-ubiquiti-
nation at Lys270,which enhances endocytosis anddegradation of
AQP2.20 To determine whether LIP5 interaction with AQP2 de-
pends on the ubiquitination state of AQP2, wt-AQP2, AQP2 that
cannot be ubiquitinated (AQP2-K270R), or constitutively ubi-
quitinated AQP2 (AQP2-Ub) were expressed in HEK293 cells
and tested for interaction. Co-immunoprecipitation assays and
subsequent immunoblotting revealed that LIP5 binds both
AQP2-K270R and AQP2-Ub, indicating that LIP5 binding to
AQP2 is independent of AQP2 ubiquitination (Figure 3B).
Role of LIP5 in AQP2 Abundance
LIP5 is implicated in sorting of proteins to the internal vesicles
of MVBs after endocytosis, from where proteins are targeted
Figure 1. Interaction of LIP5 with AQP2, AQP3, AQP4, and EGFR. (A) Yeast cells expressing LexA fused to the C-tail of wt-AQP2,
AQP2-S256A, AQP2-S256D, AQP2-E258K, AQP3, or AQP4 proteins, all in combination with GAL4-LIP5 fusion proteins, were analyzed
for interaction using -galactosidase activity assays. Yeast cells expressing the C-tails of wt-AQP2, AQP2-S256A, AQP2-S256D, and
AQP2-E258K but not those of AQP3 or AQP4 show blue staining of the colonies and thus interaction with LIP5. Sequential stop mutants
of the C-tail of AQP2 revealed that only upon deletion of region L230-D243, binding of the AQP2 C-tail with LIP5 is lost. Control yeast
cells transfected with bait and empty prey constructs did not show any -galactosidase activity. (B and C) GST or GST fused to the C-tails
of AQP2 (GST-AQP2) or AQP4 (GST-AQP4) were incubated with in vitro translated LIP5 (B) or dog kidney cytosol (C) and subjected to
GST pulldown assays. LIP5 was visualized by autoradiography (B) or immunoblotting (C). (D) For determination of whether LIP5 also
interacts with the EGFR, Xpress-tagged LIP5 was expressed alone or together with the EGFR (in duplicate) in HEK293 cells, lysed, and
subjected to EGFR immunoprecipitation. Subsequent immunoblotting of the precipitates using mouse anti–Xpress-tag antibodies
revealed that Xpress-tagged LIP5 co-precipitated with the EGFR but was not precipitated when expressed alone (top). EGFR
immunoblotting of the lysates revealed specific signals for the EGFR in lanes of cells transfected with EGFR constructs (bottom). LIP5
immunoblotting showed Xpress-tagged (exo) and endogenous (endo) LIP5 in cells transfected with LIP5 constructs (third panel).
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for lysosomal degradation,24 and LIP5 knockdown decreases
lysosomal degradation of EGFR.24 In polarized MDCK cells,
AQP2 is also degraded through the lysosomal pathway. In ad-
dition, activation of the protein kinaseC (PKC) pathway by the
phorbol-ester 12-tetradecanoylphorbol-13-acetate (TPA)
counteracts the AVP-induced translocation of AQP2 to the
apical membrane by inducing AQP2 internalization and deg-
radation.8,20 To test whether LIP5 has a similar function with
regard to AQP2, we tested whether mpkCCD cells (murine
collecting duct cells that yield expression of endogenous AQP2
protein upon treatment with dDAVP27,28) show internaliza-
tion of AQP2 upon TPA treatment. Immunocytochemistry
and confocal laser scanning microscopy analysis showed pres-
ence of endogenous AQP2 in the apical membrane with
dDAVP, which was redistributed to intracellular vesicles upon
45min of TPA treatment (Figure 4A). Furthermore, immuno-
blot analysis showed that 2 h of TPA treatment in the presence
of the protein synthesis inhibitor cycloheximide significantly
increases the degradation of existing AQP2, which was par-
tially blocked by the proteasomal inhibitor MG132 and com-
pletely blocked by chloroquine, which inhibits lysosomal degra-
dation (Figure 4B).
To investigate the effect of TPA on the half-life of AQP2, we
incubated vasopressin-stimulated mpkCCD cells for various
periods with or without TPA in the continuous presence of
cycloheximide and immunoblotted for AQP2 (Figure 4C). Af-
ter 60 min of TPA treatment, AQP2 levels were significantly
(P 0.05) decreased for TPA-treated versus control cells. Cal-
culations revealed that TPA reduced the half-life of AQP2 from
234.5 32.7 to 66.2 14.3 min.
To investigate whether LIP5 plays a role in AQP2 degrada-
tion, wemade lentiviruses driving the expression of two differ-
ent murine LIP5 (LIP5–1/2) shRNAs or a random sequence
(mock). For recognition of infected cells, the viral DNA also
encoded cytomegalovirus (CMV) promoter–driven GFP.
Testing the viruses in untransfected, dDAVP-stimulated
mpkCCD cells revealed that most cells had lost the shRNA
constructs at the time of appropriate AQP2 abundance (at 4 d
of dDAVP treatment after 4 d of cell polarization); therefore,
mpkCCD cell lines stably expressing AQP2 were generated. To
perform experiments with physiologically relevant AQP2 pro-
tein levels, we selected clones that express AQP2 at a similar or
lower level than endogenous AQP2 after stimulation with 1 nM
dDAVP by immunoblotting (data not shown). After infection of
mpkCCD-AQP2 cells with shRNA viruses, immunocytochemis-
try showed a strongly decreased LIP5 abundance in cells infected
with the LIP5-specific shRNAs (LIP5-1, LIP5-2; Figure 5A),
whereas cells infected with a virus encoding the mock shRNA
(Figure 5A) showed no difference in LIP5 protein abundance
compared with uninfected cells. This indicated that LIP5-specific
shRNAs but not viral infection itself affects LIP5 protein abun-
dance. Unfortunately, we did not succeed in co-staining for LIP5
and AQP2 in the GFP background.
To determine the effect of LIP5 knockdown on AQP2 deg-
radation, we treated cells with cycloheximide in the absence or
presence of TPA for 2 h and lysed them. Consistent with im-
munocytochemistry, subsequent immunoblot analysis for
LIP5 revealed that LIP5 shRNAs but not mock shRNA yielded
significantly reduced LIP5 protein levels (90 and 70% for
LIP5-1 and LIP5-2, respectively; Figure 5, B andC). UponTPA
treatment, AQP2 levels were significantly higher with both
shRNA virus–infected cells compared with mock virus–in-
fected cells (Figure 5, B and C, TPA). Assuming a similar
half-life for AQP2 in non–TPA-treated cells as found for non–
TPA-treated mpkCCD cells (Figure 4C), the reduced decrease
of AQP2 with TPA in LIP5 shRNA-expressing cells indicated
that knockdown of LIP5 increased the TPA-induced half-life
approximately 1.5- to 2.5-fold. Because Coomassie staining
confirmed equal protein loading (Figure 5, B and C) and there
was no effect on LIP5 or AQP2 abundance levels in mpkCCD
cells infectedwithmock shRNA virus (Figure 5A,Mock), these
data indicate that LIP5 indeed facilitates degradation of AQP2.
Interestingly, mpkCCD cells endogenously express AQP4,
which is not boundby LIP5 (Figure 1). Analysis of AQP4under
all of these conditions revealed that AQP4 abundance is not
affected by LIP5 knockdown (Figure 5, B and C), indicating
that the effect of LIP5 is specific for AQP2.
Figure 2. Localization of LIP5 in mouse kidney. (A) Alternating
mouse kidney sections were used to visualize the co-localization
of LIP5 mRNA (by in situ hybridization; 1 and 3) and AQP2 (by
immunohistochemistry; 2 and 4). LIP5 mRNA is detected in most
epithelial cells. In situ hybridization using a sense probe did not
reveal any specific staining (5). (B) Renal sections of mice receiving
water ad libitum were subjected to immunohistochemistry for
LIP5 (red) and AQP2 (green). In renal principal cells, which express
AQP2, LIP5 shows similar localization to that of AQP2 (middle). In
intercalating cells (*) and epithelial cells of other tubules (arrows),
LIP5 staining is more punctuate.
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DISCUSSION
LIP5 Specifically Interacts with the Proximal Region of
the AQP2 C-Tail Independent of AQP2
Phosphorylation or Mono-ubiquitination
We identified LIP5 to interact with the C-tail of AQP2-S256A
in yeast two-hybrid assays. Whereas AQP2 is coexpressed with
AQP3 and AQP4 in renal principal cells and all have a similar
gross architecture, yeast two-hybrid and GST pulldown analy-
ses revealed that LIP5 interacts directly and specifically with
the AQP2 C-tail only, not with the C-tails of AQP3 or AQP4
(Figure 1, A through C). Further analysis of the AQP2 C-tail
revealed that LIP5 binds region L230 to D243 of AQP2 (Figure
1A). Consistent with binding to this region of AQP2, the inter-
action of LIP5 to AQP2 is independent of AQP2 phosphoryla-
tion (at Ser256) andmono-ubiquitination (at K270) and is also
not affected by an AQP2 mutation causing NDI, because the
sites of thesemodifications are outside the LIP5 binding region
(Figure 3). The precise mode of interaction and amino acids
involved remains to be established.
LIP5 Interacts with Cargo Proteins
The MVB machinery is composed of three complexes—
ESCRT-I, -II, and-III—whichare sequentially recruited to sitesof
MVB sorting and vesicle formation. Subsequent release of ES-
CRT-III from the membrane requires Vps4 ATPase activity and
allows the ESCRTmachinery to recycle throughmultiple rounds
of luminal vesicle formation. So far, LIP5 has
been shown to interact withVps4 and several
ESCRT-III components, including CHMP5,
CHMP1B, CHMP2A, and CHMP3.24,29–33
Our data reveal for the first time that LIP5
also interacts with cargo proteins, because
AQP2 aswell as theEGFR specifically co-pre-
cipitatedwithLIP5 (Figure 1). Itwill be inter-
esting tounravel towhichLIP5 segment these
twoproteinsbindandwhether these twopro-
teins compete with CHMPs for binding to
Vps4.
LIP5 Is Involved in the Lysosomal
Degradation Pathway of AQP2
Membrane proteins targeted for lysosomal
degradation are sorted into vesicles that
bud into MVBs. These MVBs can serve as
long-term storage compartments, fusewith
lysosomes to deliver the internal vesicles
and their contents for degradation, or fuse
with the plasma membrane to release the
vesicles as extracellular exosomes. MVB
vesicle formation and protein sorting re-
quire a set of class-E vacuolar protein sort-
ing (VPS) proteins.34–36 Most class-E pro-
teins function as components of one of the
three ESCRT complexes, which are sequen-
tially recruited to sites of MVB sorting and vesicle formation.
The ESCRT-III proteins are the last to assemble, forming a
membrane-associated lattice that functions in the final stages
of this process.Via direct protein–protein interactions, Vps4 is
recruited toMVBs, which induces the release of the ESCRT-III
complex from the membrane.34,36
Emerging evidence points toward a role for LIP5 dimers in
the disassembly of the ESCRT-III complex by stimulatingVps4
ATPase activity, which occurs directly through interaction be-
tween the conserved C-terminal VSL domain of LIP5 and
Vps4.31–33 Consistently, deletion of Vta1 (the yeast LIP5 ortho-
logue) in yeast results in altered vacuolar morphology,29 and
knockdown of LIP5 in mammalian cells facilitates downregu-
lation of EGFR.24
Several data suggest a similar role for LIP5 in AQP2 regula-
tion in principal cells: First, LIP5 is coexpressed with AQP2 in
renal principal cells (Figure 2) and LIP5 has been identified in
AQP2-containing exosomes isolated from urine (My012 pro-
tein).37 Second, renal LIP5 interacts specifically with the C-
terminal tail of AQP2 (Figure 1). Third, LIP5 facilitates the
lysosomal degradation of AQP2: Whereas induced LIP5 over-
expression in MDCK-AQP2 cells did not affect AQP2 abun-
dance (Supplemental Figure 3) or translocation to the apical
membrane, knockdown of LIP5 abundance resulted in a 1.5-
to 2.5-fold increase in the AQP2 half-life after TPA treatment
(Figure 5, B and C), a condition known to induce AQP2 inter-
nalization and degradation8 (Figure 4). Considering our find-
Figure 3. LIP5 interaction with physiologically modified AQP2. (A) For determination
of whether LIP5 binding to AQP2 depends on the phosphorylation state of AQP2, LIP5
was expressed together with wt-AQP2, AQP2-S256D, and AQP2-S256A in HEK293
cells; lysed; and subjected to LIP5 immunoprecipitation. Subsequent immunoblotting
of the precipitates demonstrated that wt-AQP2, AQP2-S256D, and AQP2-S256A
co-precipitated with LIP5 (top). Immunoblotting of the lysates revealed similar signals
for AQP2 in lanes of cells transfected with AQP2 protein constructs (middle) and for
endogenous (endo) and exogenous (exo) LIP5 in cells transfected with LIP5 constructs
(bottom). (B) For determination of whether LIP5 binding to AQP2 depends on the
ubiquitination state of AQP2, LIP5 was expressed together with wt-AQP2, AQP2-
K270R, and AQP2-Ub in HEK293 cells. Subsequent cell lysis and LIP5 immunoprecipi-
tation followed by immunoblotting showed that wt-AQP2, AQP2-K270R, and
AQP2-Ub co-precipitated with LIP5 (top). Immunoblotting of the lysates revealed
equal signals for AQP2 in lanes of cells transfected with wt-AQP2, AQP2-K270R, and
AQP2-Ub constructs (middle) and for endogenous (endo) and exogenous (exo) LIP5 in
cells transfected with LIP5 constructs LIP5 (bottom).
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ing that AQP2 levels seemed somewhat increased in LIP5
shRNA versus mock cells without TPA treatment (Figure 5, B
and C), the half-life of AQP2 in LIP5 knockdown cells without
TPA treatment may be higher than that of AQP2
in dDAVP-stimulated mpkCCD cells (Figure
4C); therefore, the estimated increase in AQP2
half-life with LIP5 knockdown after TPA treat-
ment should be taken as a rough estimate.
Under the tested conditions, the effect of LIP5
knockdown is clear upon treatment with TPA but
not without TPA treatment, which can be ex-
plained as follows: At anymoment in time, AQP2
resides at several locations in the cell (endoplas-
mic reticulum, Golgi, storage vesicles, plasma
membrane, recycling vesicles, MVBs, and lyso-
somes), and the steady-state localization of AQP2
is a balance regulated by extracellular and intra-
cellular signals, such as the presence of AVP, and
cAMP-dependent phosphorylation or activation
of the PKC pathway. TPA-induced degradation
of AQP2 in mpkCCD cells mainly occurs via ly-
sosomes (Figure 4B) and, as illustrated by the
large half-life of AQP2 of nearly 4 h (Figure 4C),
only a small fraction of AQP2 is targeted for lyso-
somal degradation in the tested 2-h period under
non-TPA conditions. With the TPA-induced in-
ternalization and lysosomal degradation of
AQP220 (Figure 4), which decreases the AQP2
half-life to approximately 70 min, more AQP2
will thus pass LIP5 on its way toMVBs/lysosomes
for the 2 h measured, and, therefore, the effect of
(the absence of) LIP5 on AQP2 is larger and bet-
ter detectable under these conditions. The partial
inhibition of AQP2 degradation in our LIP5
shRNA experiments may suggest that, like its
yeast orthologue Vta1,33 LIP5 has only a modula-
tory role in the lysosomal degradation of AQP2;
however, this cannot be deduced from our exper-
iments, because as a result of incomplete infec-
tion and/or shRNA knockdown, our shRNA-ex-
pressing cells were not devoid of LIP5 (Figure 5B).
Onthebasisof thesedata,wepropose the follow-
ing model for the role for LIP5 in the regulation of
AQP2 inprincipal cells: After stimulationwithAVP
and translocation ofAQP2 to the apicalmembrane,
renal water reabsorption will occur, which may be
increased by an extended presence of AQP2 in the
plasma membrane through an interaction with
MAL.22 With removal of AVP or activation of the
PKCpathway,which is thought to followbindingof
hormones such as endothelin, PGE2, and ATP,
AQP2 is ubiquitinated at Lys270, which signals its
endocytosis.20 After recruitment to clathrin-coated
vesicles, AQP2 is then endocytosed from the apical
membrane involving direct interaction with heat-
shock protein 70.23Via early endosomes, AQP2 is then sorted via
ESCRT proteins and interaction with LIP5 to inner vesicles of
MVBs, fromwhere it canbe targeted to lysosomes fordegradation
Figure 4. TPA induces internalization and lysosomal degradation of AQP2 in
mpkCCD cells. (A) TPA induced internalization of AQP2. For testing whether phor-
bol esters also induce internalization of AQP2 in mpkCCD cells, a monolayer of
polarized mpkCCD cells stably expressing exogenous AQP2 (mpkCCD-AQP2) was
stimulated with forskolin for 45 min followed by stimulation with forskolin only
(TPA) or together with TPA (TPA) for 45 min. Subsequent immunocytochemistry
and confocal laser scanning microscopy demonstrated internalization of AQP2
upon TPA treatment. (B) TPA induces lysosome-mediated degradation of AQP2.
MpkCCD-AQP2 cells were stimulated with forskolin for 45 min, followed by incu-
bation with forskolin alone or together with cycloheximide. Moreover, cells treated
with forskolin and cycloheximide were additionally treated with or without TPA
alone or TPA together with the proteasome blocker MG132 or the lysosome
blocker chloroquine. All treatments after stimulation with forskolin were for 2 h, after
which the cells were lysed. Immunoblotting for AQP2 revealed that co-incubation
with chloroquine but not MG132 counteracted the TPA-induced increase in AQP2
degradation. Immunoblotting was performed in at least two independent experi-
ments performed in triplicate. Quantification of AQP2 levels showed significant
effects (two-tailed t test; *P  0.05, **P  0.01). (C) TPA reduces the half-life of
existing AQP2. MpkCCD-AQP2 cells were grown and stimulated to induce AQP2
expression as described in A. Cells were then treated with cycloheximide alone or
together with TPA for the indicated periods. Cells were then lysed and analyzed
usingWestern blotting using AQP2 antibodies (top), followed by semiquantification
using densitometry. The data are plotted as a percentage of the control (mpkCCD
cells grown 4 d in the presence of dDAVP). Quantification of AQP2 levels showed
significant effects (two-tailed t test; *P  0.05).
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or released as exosomes from the cells into urine (Figure 6).37
Unfortunately, we were not able to co-immunoprecipitate AQP2
withLIP5 frommousekidneyhomogenates,whichmaybedue to
a reduced abundance of LIP5 or low level of AQP2–LIP5 interac-
tion in the kidney.
The binding of LIP5 to the proximal region of the AQP2
C-tail and its independence of the ubiquitination and phosphor-
ylation status of AQP2 (Figure 3) is in line with the
finding that TPA-induced internalization of AQP2
constitutively phosphorylated at S256 still leads to
its degradation8,38 and that AQP2 degradation is
well detectable only at 2 h after TPA treatment, at
which point AQP2 is not detectably ubiquitinated
anymore.20 Recently, AQP2 was found to be phos-
phorylated at other sites in its C-terminus.39 It re-
mains to be establishedwhether phosphorylation of
these sites influences LIP5 binding to AQP2.
Interestingly, LIP5 has also been reported to
interact with the lysosomal trafficking regulator
LYST,40 which is a cytosolic protein of 425 kD
with a putative function in lysosome-related or-
ganelles.41 Yeast two-hybrid screens with LYST
identified several putative partners, some of
which have been shown to co-localize (HRS)42 or
be involved (calmodulin)1 in the regulation of
AQP2. If LYST is expressed in collecting duct
cells, then LYST may be a scaffolding protein in-
volved in the degradation of AQP2.
Moreover, calmodulin has been shown to inter-
act with proximal C-terminal tail of AQP0,43 the re-
gion bound by LIP5 in AQP2. Although these re-
gions are similar between AQP0 and AQP2, we
could not detect binding between heterologously
expressed calmodulin and the AQP2 C-tail in GST
pulldown experiments (data not shown).
In summary, we have identified that LIP5 is co-
expressed with AQP2 in renal principal cells, inter-
actswith theproximalC-tailofAQP2,and facilitates
its lysosomal degradation. Our data thus indicate
that LIP5 plays an important role in theMVB/lyso-
somal targeting of AQP2, as induced byAVP-coun-
teracting hormones, after which it will be degraded
or expelled from the cells into urine. It will be inter-
esting to seehowLIP5 structurally couples toAQP2,
whether the degradation of other cargo proteins is
facilitated by direct interaction with LIP5, and
whether LIP5 also affects AQP2 stability in vivo.
CONCISE METHODS
Yeast Two-Hybrid
cDNAs encoding wild-type and mutant AQP2 C-ter-
mini starting at amino acid Phe224 were generated by
standard PCR reactions using AQP2-C-EcoRI (5-
GATCGGAATTCCCGCCAGCCAAGAGCCT-3) as a
forward primer and AQP2-C-XhoI as a reverse primer. As templates,
pCB6-wtAQP2, pCB6-AQP2-S256A, and pCB6-AQP2-S256D8 were
used. cDNAs encoding truncated AQP2 C-tail proteins were gen-




Figure 5. LIP5 silencing results in reduced lysosomal degradation of AQP2.
MpkCCD cells stably transfected with AQP2 were infected with viruses express-
ing two different LIP5 shRNAs (LIP5-1, LIP5-2) at a multiplicity of infection of 20.
Four days later and after stimulation with forskolin for 45 min, the cells were
incubated with cycloheximide in the absence or presence of TPA for 2 h. (A)
Cells were subjected to immunocytochemistry for GFP (left) and LIP5 (right). In
mock shRNA-expressing cells, LIP5 abundance was not affected. LIP5 shRNA
expressing cells showed decreased LIP5 staining. (B) Cell lysates were immuno-
blotted for GFP, LIP5, and AQP2. Immunoblotting for GFP serves as a measure
for infection efficiency, whereas Coomassie staining demonstrates equal protein
loading. A representative immunoblot of two experiments is shown. (C) Quan-
tification of the immunoblot signals of two independent experiments performed
in triplicate. The signals were scanned, and the amounts of LIP5, AQP2, AQP4,
and total protein were quantified in arbitrary units  SEM. *Significant differ-
ence from mock-treated cells (two-tailed t test; P  0.05).
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CTCCC-3), or AQP2-Q263X (GATCCTCGAGCTACGGCGAGTG-
CAGCTCCAC-3) as a reverse primer (in all mutagenesis primers
introduced, mutations are underlined and restriction sites are in
italic). The obtained fragments were digested with EcoRI and XhoI
and cloned into the EcoRI and SalI sites of pBTM116.44 The C-
terminal tails of AQP3 (amino acids M264-I292) and AQP4 (amino
acids V251 through V323) were cut from pGBT9-AQP3 and pGBT9-
AQP445 using EcoRI and PstI and cloned into the corresponding sites
of pBTM116. For all constructs, introduction of only the desired mu-
tation was confirmed by DNA sequence analysis.
To identify AQP2 interacting proteins, we screened a GAL4 cDNA
library of adult mouse whole kidneys (MATCHMAKER, Clontech,
Palo Alto, CA) against a bait of the AQP2-S256A C-terminal tail. For
this, L40 yeast cells (MATa, trp1, leu2, his3, LYS2::lexA-HIS3,
URA3::lexA-lacZ) were transfected with the pBTM116-S256A con-
struct. After 3 d, colonies were picked, grown in medium, pelleted,
and analyzed for their LexA-C-tail expression using AQP2 and LexA
immunoblot analysis. For library screening, four independent colo-
nies expressing LexA-AQP2-S256Awere grown to A546 2 at 30°C,
260 rpm in 100 ml of SD-Trp medium and used to inoculate 1 L of
YPDA to 0.2 A600. At 0.8 A600, the cells were collected by centrifuga-
tion at 4200 g at 4°C for 15 min, washed twice with sterile distilled
H2O, pelleted at 1300 g (10min, 4°C), and transfected according to
Gietz et al.46 using 50g of Library DNA. After incubation for 30min
at 30°C and a 30 min heat shock at 42°C, cells were harvested by
centrifugation at 1900  g for 3 min, washed with distilled H2O,
resuspended in 20 ml of distilled H2O, and plated on 25 selective
SD-Trp-His-Leu dishes of 245  245 mm. After 5 d, colonies were
tested for -galactosidase expression by a colony lift assay.47 For this,
colonies were transferred onto 3-mm Whatmann filters, permeabil-
ized in liquidN2, and overlaidwith 0.2mg/mlX-gal inTBSY (150mM
NaCl, 50 mM Tris-HCl [pH 7.4], and 0.8% agarose). Colonies that
turned blue were transferred to selective plates and rescreened for
LacZ activity as already described. From colonies that remained pos-
itive after rescreening, DNA was isolated,48 electroporated to electro-
competent KC8 cells (2.3 kV, 25 F, and 200 ), and plated on M9-
Leu plates. After checking insert sizes ofDNA from three independent
colonies by BglII digestion, L40 cells were retransformed with prey
DNA in combination with either pBTM116 or pBTM116-AQP2-
S256A to verify specificity of the isolated prey plasmid for binding to
theAQP2-S256AC-tail by a colony lift assay. Prey plasmids giving rise
to blue colonies when transformed with pBTM116-AQP2-S256A/D
but not with pBTM116 were subjected to DNA sequence analysis to
identify the prey cDNA. Transformation of one or two plasmids to
L40 yeast cells at a time was done by using 1g of plasmid equivalents
in a downscaled library transformation protocol and a selection for
colonies on appropriate SD plates for 3 to 4 d.
Pulldown Assays
For the expression of wt-AQP2 C-tail as a GST fusion protein, a stan-
dard PCRwas done using the forward primer AQP2-CtermFWD (5-
GGAATTCCCAGCCAAGAGCCTGTCG-3) and the reverse primer
AQP2-C-XhoI on a pBS-AQP249 template. The PCR fragment was
digested with EcoRI-XhoI and cloned into corresponding sites of
pGEX4T-1 (Amersham Biosciences, Freiburg, Germany). For GST-
AQP4 expression, we used a pGEX1 vector containing the C-tail of
AQP4.50 Tomake aGST-LIP5 expression construct, pACT2 clone 14b
(identified from library screening) was cut with EcoRI and XhoI, and
the cDNA fragment encoding full-length LIP5 was isolated and
cloned into the corresponding sites of pGEX6.1 (Amersham Bio-
sciences, Freiberg, Germany).
GST, GST-AQP2, and GST-AQP4 production in BL21-DE3 bac-
teria was induced by IPTG and isolated with prewashed Glutathione-
Sepharose 4B beads. LIP5 was produced by in vitro transcription/
translation using the Riboprobe-T7 system (Promega, Leiden,
Netherlands) in the presence of 35S-methionine/cysteine (Redivue
Promix; Amersham Biosciences, Uppsala, Sweden) and incubated
with the GST fusion protein beads, rotating overnight at 4°C. Bound
LIP5 was eluted by boiling the samples in Laemmli sample buffer and
analyzed by SDS-PAGE. Pulled-down LIP5 was visualized using a
STORM phosphor imager (Amersham Biosciences, Uppsala, Swe-
den).
Cytosol of dog kidneys was prepared by crushing the tissue in a
blender and subsequent homogenization in 20 mMHEPES, 100 mM
NaCl, 5 mM MgCl2, 1 mM dithiothreitol, 1 mM PMSF, 5 g/ml
Figure 6. Model for LIP5 function in the regulation of AQP2. On
the basis of our findings, we propose the following model for LIP5
function in AQP2 regulation: After AVP-induced translocation of
AQP2 to the apical membrane, water will be reabsorbed from the
pro-urine. Interaction with MAL may increase water reabsorption
further by extending the presence of AQP2 in the plasma mem-
brane. Upon removal of AVP or activation of the PKC pathway,
AQP2 is mono-ubiquitinated by a presently unknown ubiquitin E3
ligase, and, subsequently, endocytosis will occur. AQP2 is re-
cruited to clathrin-coated vesicles and endocytosed from the
apical membrane involving direct interaction with heat-shock pro-
tein 70 (HSP70). Via early endosomes (EE), AQP2 is then sorted
via ESCRT-I, -II and, -III protein complexes to the limiting mem-
brane of MVBs. There, interaction with LIP5 and LIP5-facilitated
activity of VPS4 AATPase mediates translocation of AQP2 from
the limiting membrane to inner vesicles of MVBs, from where it
can be targeted to lysosomes for degradation or released as
exosomes from the cells into urine.
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leupeptin, and 5 g/ml pepstatin using a potter (PotterS, Braun Bio-
tech, Melsungen, Germany). Cytosol was cleared by centrifugation at
33,000 rpm in a Ti45 rotor in a Beckmanultracentrifuge for 1 h at 4°C.
The supernatantwas preincubated for 1 hwith glutathione-Sepharose
4B beads containing GST and subsequently incubated with GST,
GST-AQP2, or GST-AQP4 glutathione-Sepharose 4B beads over-
night at 4°C. After binding, the beads were washed with 25 mM Tris
(pH 7.5), 0.5 mM EDTA, and 1% Triton-X100, and bound proteins
were eluted by shaking in 1.5 M NaCl, 25 mM Tris (pH 7.5), and 0.5
mMEDTA at room temperature for 1 h. Samples were desalted using
Biospin columns (Biorad, Hercules, CA). Isolated proteins were ana-
lyzed by SDS-PAGE and immunoblotting.
Empty or transfected COS cells were lysed in 300 l of lysis buffer
with 1%NP40. For LIP5 depletion, lysates were incubated for 2 hwith
4 l of LIP5 antiserum and 40 l of protein A-agarose beads (Kem-
En-Tec A/S, Copenhagen, Denmark). Lysates were then incubated
with GST-AQP2 glutathione-Sepharose 4B beads and further pro-
cessed as described already.
Expression in Eukaryotic Cells
For expression of LIP5 in eukaryotic cells, an EcoRI-XhoI fragment
encoding full-length LIP5 was isolated from the pACT2 clone 14b,
identified from library screening, and ligated into the corresponding
sites of pCDNA3. Expression constructs encoding wild-type AQP2 or
the S256A, S256D, K270R, and AQP2-Ub mutants were as described
previously.7,20 pCDNA3-EGFR was provided by Prof. Y. Yarden (De-
partment of Biologic Regulation, Weizmann Institute of Science, Re-
hovot, Israel).51 HEK293 cells were maintained in DMEM (Biowit-
taker, Verviers, Belgium) supplemented with 10% FCS. For transient
transfections, HEK293 cells were seeded at 1.2  105 cells/cm2 in
six-well plates. Four hours after seeding, cells were transfected using
polyethylenimine (Polysciences, Eppelheim, Germany). A total of 3.5
g of circular DNA and 14 l of polyethylenimine (1 g/l) were
added to 80 l of OptiMEM medium (Life Technologies Europe,
Breda, Netherlands), vortexed, and incubated at room temperature
for 20 min. Subsequently, the mixture was added to the cells and
incubated overnight. Three days after transfection, cells were lysed in
IP lysis buffer (1% Triton X-100, 150 mM NaCl, and 25 mMHEPES
[pH 7.4]) and incubated with rabbit anti-LIP5 antibodies, mouse
anti-Xpress, or mouse anti-EGFR 528 (Santa Cruz Biotechnology,
Santa Cruz, CA) immobilized on protein A-agarose beads (Kem-En-
Tec A/S) overnight at 4°C. Immunoprecipitated proteins were ana-
lyzed by immunoblotting.
In Situ Hybridization
LIP5 cDNA templates with a T7 RNA polymerase promoter sequence
(underlined inprimer sequences) at the5or3endwereused togenerate





CATTGTCTGCATACA-3 (antisense) primers, respectively. 11-UTP
dioxigenin (DIG)-labeled probes of these templates were made in vitro
using T7 RNA polymerase (Roche Diagnostics, Almere, Netherlands).
For preparation of mouse kidney sections, mice were transcardially
perfused with ice-cold 0.6% NaCl solution for 5 min, followed by
Bouin’s fixative for 15min. After dissection, kidneys were postfixed in
Bouin’s fixative for 24 h. Then, kidneys were dehydrated in a graded
series of ethanol and xylene and embedded in paraffin. Seven-mi-
crometer sections were mounted on poly-L-lysine–coated slides and
dried for 16 h at 37°C before they were rehydrated in a graded series of
ethanol. Tissue penetrationwas enhanced by incubation in 0.1%pep-
sin in 0.2 M HCl for 15 min at 37°C, followed by fixation in 4%
paraformaldehyde in PBS for 5 min and incubation in 1% hydrox-
ylammoniumchloride for 15min. After this, sectionswere dehydrated
in ethanol and air dried. Hybridization took place for 1 h at 55°C in
hybridization buffer (10% sodium dextran sulfate, 50% formamide,
4 salt and sodium citrate (SSC), 1Denhardt’s and 200g/ml yeast
tRNA; 1 SSC	 0.15 MNaCl and 0.015 M sodium citrate) with 500
ng/ml DIG-labeled probe. After stringency washes in 2 SSC, 1
SSC, 0.5 SSC, and 0.1 SSC for 30min at 37°C, sections were rinsed
for 10min in Tris-buffered saline (TBS), blocked in blocking solution
(1% BSA and 2% normal goat serum in TBS) for 30 min, and incu-
batedwith alkaline phosphatase (AP)-conjugated sheep anti-DIG Fab
fragments (1:500; Roche Diagnostics) in blocking solution for 16 h at
4°C. After three washes of 10min in TBS and one wash of 5min in AP
buffer (100 mM Tris and 100 mM NaCl [pH 9.5]), sections were
stained in 350g/ml 4-nitro blue tetrazolium chloride and 175g/ml
5-bromo-4-chloro-3-indolyl-phosphate (Roche Diagnostics) in AP
buffer until color development was sufficient. Then, sections were
washed twice with distilledH2O andmounted inMowiol. Alternating
sectionswere used forAQP2 immunohistochemistry. Aftermounting
of fixed sections on poly-L-lysine–coated slides and rehydration in
graded series of ethanol, sections were washed with TBS, incubated
with 1% H2O2 in TBS for 15 min to quench endogenous peroxidase
activity, rinsed with TBS, incubated with 1:100 diluted rabbit anti-
AQP2 antibodies in blocking buffer, washed three times with TBS,
and incubated for 1 h in 1:100 diluted donkey anti-rabbit antibodies
coupled to horseradish peroxidase (Jackson ImmunoResearch Labo-
ratories, West Grove, PA). After washing three times in TBS, sections
were incubated in diaminobenzidene until color development was
sufficient. Then, sections were dehydrated in graded series of alcohol
and ethylene and mounted in Entellan (Merck, Darmstadt, Ger-
many). A sense LIP5 cRNA probe was taken along as a negative con-
trol for the specificity of the LIP5 mRNA hybridization.
mpkCCD Cells and shRNA Assays
MpkCCD cells (clone 1427) were grown in modified defined medium
(DMEM:Ham’s F12 1:1 vol/vol; 60 nM sodium selenate, 5 g/ml
transferrin, 2 mM glutamine, 50 nM dexamethasone, 1 nM triiodo-
thyronine, 10 ng/ml EGF, 5g/ml insulin, 20mMD-glucose, 2%FCS,
and 20mMHEPES [pH7.4]) at 37°C in an air atmosphere of 5%CO2.
The medium was replaced every 2 d. Exponentially growing cells (at
approximately 70% confluence)were trypsinized and seeded at a den-
sity of 1.5  105 cells/cm2 on semipermeable filters (Transwell,
0.4-mpore size; Corning Costar, Cambridge, MA) of 1.13 cm2. The
cells remained in culture for a total period of 8 d before being ana-
lyzed. The cells were treated for the last 96 hwith 1 nMdDAVP to only
the basolateral side to induce AQP2 expression maximally. TPA (0.1
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M), cycloheximide (50 M), MG132 (20 M), and chloroquine
(100 M) were administered to both the apical and the basolateral
compartments for the indicated time periods.
To make pLV-CMV-GFP-shRNA-LIP5 constructs for the LIP5
shRNA assays, we first created the pTER-LIP5 construct. Phosphory-
lated LIP5-specific oligonucleotides (10 g) were annealed in 100 l
of 25mMKCl by incubating themixture at 95°C for 2min and slowly
cooling to room temperature. A total of 1l of themixturewas ligated
into the BglII- and HindIII-digested pTER vector.52 The following








To generate the lentiviral LIP5 shRNA constructs, we inserted the PstI
fragments from the pTER-LIP5 constructs containing the H1 pro-
moter and LIP5 shRNA sequences into the corresponding site of pLV-
CMV-GFP.53
MpkCCD cells were stably transfected with pCB6-AQP2 using the
calcium-phosphate precipitation technique as described previously.54
Third-generation lentiviruses were produced by co-transfection of
the packaging vectors pRSV-Rev, pMDL g/p RRE, and pMD2G
(Tronolab, Lausanne, Switzerland) and the transfer vector pLV-
CMV-GFP-shRNA-LIP5 into human embryonic kidney 293T cells as
described previously.55 The titer was determined by a p24 HIV ELISA
(Murex Diagnostics, Dartford, United Kingdom).MpkCCD cells sta-
bly expressing AQP2were infectedwith lentivirus immediately before
being plated in the presence of Polybrene (8g/ml) using amultiplic-
ity of infection of 20. The next day, medium was replaced. Immuno-
blotting and immunocytochemistry were performed 4 d after infec-
tion. The half-life of AQP2 was determined on the basis of the best
fitting model of regression.
LIP5 Antibodies
To obtain rabbit anti-LIP5 antibodies, we induced expression of sol-
uble GST-LIP5 with IPTG in DH5 bacteria transfected with
pGEX6.1-LIP5 (made as described in the Pulldown Assays section)
and isolated using glutathione-Sepharose 4B beads (AmershamPhar-
macia Biotech, Uppsala, Sweden). After complete bleeding of the rab-
bits, anti-GST antibodies were removed by passing the serum over a
GST-coupled Affi-gel 15 column (Amersham Pharmacia Biotech).
Then, the flow-throughwas passed over aGST-LIP5–coupledAffi-gel
15 column, and the antibodies were eluted with 0.1 M glycine (pH
2.8), after which they were directly neutralized in 5 PBS (pH 7.4).
Immunohistochemistry
Mice were perfused with 1% (wt/vol) paraformaldehyde-lysine-pe-
riodate.56 The kidneys were removed, cut into 2- to 3-mm sections,
and incubated in paraformaldehyde-lysine-periodate for 2 h. After
fixation, the kidneys were dehydrated and embedded in paraffin.
Five-micrometer sections were cut, stretched in 37°Cwater, and dried
on gelatin-coated object glass (Menzel Gla¨ser, Braunschweig, Ger-
many) for at least 1 h at 37°C. Then, the sections were deparaffinized
with xylol; rehydrated subsequently with 100, 96, 90, 80, 70, and 50%
ethanol and water; and mounted in mowiol. Immunocytochemistry
was done as described for MDCK cells.57 For detection of LIP5 and
AQP2, the sections were incubated with affinity-purified rabbit anti-
LIP5 antibodies (1:25), goat anti-rabbit antibodies coupled to Alexa
594 (Molecular Probes, Eugene, OR; 1:100), and, subsequently, with
affinity-purified guinea pig anti-AQP258 and goat anti-guinea pig an-
tibodies coupled to Alexa 488 (Molecular Probes; 1:100).
Immunoblotting
Immunoblotting was done as described previously.59 As antibodies,
affinity-purified rabbit anti-AQP2 (1:300058), rabbit anti-LIP5
(1:1000), rabbit anti-AQP4 (1:150058), rabbit anti-GFP (1:5000; pro-
vided by Dr. B. Wieringa, UMC Nijmegen, Nijmegen, Netherlands),
guinea pig anti-AQP2 (1:400058),mouse anti-Xpress (1:5000), or rab-
bit anti-EGFR 1005 (1:1000; Santa Cruz Biotechnology) was used. As
secondary antibodies, goat anti-rabbit, goat anti-guinea pig, or sheep
anti-mouse antibodies coupled to horseradish peroxidase (Sigma, St.
Louis, MO; 1:5000) were used.
ACKNOWLEDGMENTS
P.M.T.D. is a recipient of a VICI grant (865.07.002) of the Nether-
lands Organization for Scientific Research (NWO). This research was
supported by grants from the Dutch Organization of Scientific Re-
search (NWO-MW 902-18-292) to P.M.T.D. and P.v.d.S., and from
the European Union (RTN aquaglyceroporins; 035995-2), kidney
foundation (C03.2060), UMC St Radboud (2004-55) and NWO
(865.07.002) to P.M.T.D.
We thankRonnieWismans andTonyCoenen for superb technical
support and Dr. S. Gisler (Department Physiology, University of Zu-
rich, Zurich, Switzerland) for sending us material and sharing his




1. Chou CL, Yip KP, Michea L, Kador K, Ferraris JD, Wade JB, Knepper
MA: Regulation of aquaporin-2 trafficking by vasopressin in renal
collecting duct: Roles of ryandoine-sensitive Ca2 stores and calmod-
ulin. J Biol Chem 275: 36839–36846, 2000
2. Agre P, King LS, Yasui M, Guggino WB, Ottersen OP, Fujiyoshi Y,
Engel A, Nielsen S: Aquaporin water channels: From atomic structure
to clinical medicine. J Physiol 542: 3–16, 2002
3. Deen PMT, Van Balkom BWM, Kamsteeg EJ: Routing of the aqua-
porin-2 water channel in health and disease. Eur J Cell Biol 79:
523–530, 2000
4. Chou CL, Christensen BM, Frische S, Vorum H, Desai RA, Hoffert JD, de
Lanerolle P, Nielsen S, Knepper MA: Non-muscle myosin II and myosin
light chain kinase are downstream targets for vasopressin signaling in the
renal collecting duct. J Biol Chem 279: 49026–49035, 2004
BASIC RESEARCHwww.jasn.org
J Am Soc Nephrol 20: 990–1001, 2009 LIP5 Directs AQP2 Degradation 999
5. Stefan E, Wiesner B, Baillie GS, Mollajew R, Henn V, Lorenz D, Furkert
J, Santamaria K, Nedvetsky P, Hundsrucker C, Beyermann M, Krause
E, Pohl P, Gall I, MacIntyre AN, Bachmann S, Houslay MD, Rosenthal
W, Klussmann E: Compartmentalization of cAMP-dependent signaling
by phosphodiesterase-4D is involved in the regulation of vasopressin-
mediated water reabsorption in renal principal cells. J Am Soc Neph-
rol 18: 199–212, 2007
6. McSorley T, Stefan E, Henn V, Wiesner B, Baillie GS, Houslay MD,
Rosenthal W, Klussmann E: Spatial organisation of AKAP18 and PDE4
isoforms in renal collecting duct principal cells. Eur J Cell Biol 85:
673–678, 2006
7. Kamsteeg EJ, Heijnen I, van Os CH, Deen PMT: The subcellular
localization of an aquaporin-2 tetramer depends on the stoichiometry
of phosphorylated and nonphosphorylated monomers. J Cell Biol
151: 919–930, 2000
8. Van Balkom BWM, Savelkoul PJ, markovich D, Hofman E, Nielsen S,
van der Sluijs P, Deen PMT: The role of putative phosphorylation sites
in the targeting and shuttling of the aquaporin-2 water channel. J Biol
Chem 277: 41473–41479, 2002
9. Katsura T, Gustafson CE, Ausiello DA, Brown D: Protein kinase A
phosphorylation is involved in regulated exocytosis of aquaporin-2 in
transfected LLC-PK1 cells. Am J Physiol 41: F816–F822, 1997
10. Nishimoto G, Zelenina M, Li D, Yasui M, Aperia A, Nielsen S, Nairn AC:
Arginine vasopressin stimulates phosphorylation of aquaporin-2 in rat
renal tissue. Am J Physiol 276: F254–F259, 1999
11. Christensen BM, Zelenina M, Aperia A, Nielsen S: Localization and
regulation of PKA-phosphorylated AQP2 in response to V(2)-receptor
agonist/antagonist treatment. Am J Physiol Renal Physiol 278: F29–
F42, 2000
12. De Mattia F, Savelkoul PJ, Kamsteeg EJ, Konings IB, van der SP,
Mallmann R, Oksche A, Deen PM: Lack of arginine vasopressin-in-
duced phosphorylation of aquaporin-2 mutant AQP2–R254L explains
dominant nephrogenic diabetes insipidus. J Am Soc Nephrol 16:
2872–2880, 2005
13. McDill BW, Li SZ, Kovach PA, Ding L, Chen F: Congenital progressive
hydronephrosis (cph) is caused by an S256L mutation in aquaporin-2
that affects its phosphorylation and apical membrane accumulation.
Proc Natl Acad Sci U S A 103: 6952–6957, 2006
14. Kuwahara M, Iwai K, Ooeda T, Igarashi T, Ogawa E, Katsushima Y,
Shinbo I, Uchida S, Terada Y, Arthus MF, Lonergan M, Fujiwara TM,
Bichet DG, Marumo F, Sasaki S: Three families with autosomal dom-
inant nephrogenic diabetes insipidus caused by aquaporin-2 muta-
tions in the C-terminus. Am J Hum Genet 69: 738–748, 2001
15. Mulders SM, Bichet DG, Rijss JPL, Kamsteeg EJ, Arthus MF, Lonergan
M, Fujiwara M, Morgan K, Leijendekker R, van der Sluijs P, van Os CH,
Deen PMT: An aquaporin-2 water channel mutant which causes auto-
somal dominant nephrogenic diabetes insipidus is retained in the
Golgi complex. J Clin Invest 102: 57–66, 1998
16. Kamsteeg EJ, Wormhoudt TA, Rijss JPL, van Os CH, Deen PMT: An
impaired routing of wild-type aquaporin-2 after tetramerization with
an aquaporin-2 mutant explains dominant nephrogenic diabetes in-
sipidus. EMBO J 18: 2394–2400, 1999
17. Kim SW, Jeon YS, Lee JU, Kang DG, Kook H, Ahn KY, Kim SZ, Cho
KW, Kim NH, Han JS, Choi KC: Diminished adenylate cyclase activity
and aquaporin 2 expression in acute renal failure rats. Kidney Int 57:
1643–1650, 2000
18. Kuwahara M, Iwai K, Uchida S, Gu Y, Terada Y, Sato K, Asai T, Bichet
D, Sasaki S, Marumo F: A novel mutation in the aquaporin-2 (AQP2)
gene causing autosomal dominant nephrogenic diabetes insipidus
[Abstract]. J Am Soc Nephrol 9: 390A, 1998
19. Marr N, Bichet DG, Lonergan M, Arthus MF, Jeck N, Seyberth HW,
Rosenthal W, van Os CH, Oksche A, Deen PMT: Heteroligomerization
of an aquaporin-2 mutant with wild-type aquaporin- 2 and their
misrouting to late endosomes/lysosomes explains dominant nephro-
genic diabetes insipidus. Hum Mol Genet 11: 779–789, 2002
20. Kamsteeg EJ, Hendriks G, Boone M, Konings IB, Oorschot V, van der
SP, Klumperman J, Deen PM: Short-chain ubiquitination mediates the
regulated endocytosis of the aquaporin-2 water channel. Proc Natl
Acad Sci U S A 103: 18344–18349, 2006
21. Noda Y, Horikawa S, Furukawa T, Hirai K, Katayama Y, Asai T, Kuwa-
hara M, Katagiri K, Kinashi T, Hattori M, Minato N, Sasaki S: Aqua-
porin-2 trafficking is regulated by PDZ-domain containing protein
SPA-1. FEBS Lett 568: 139–145, 2004
22. Kamsteeg EJ, Duffield AS, Konings IB, Spencer J, Pagel P, Deen PM,
Caplan MJ: MAL decreases the internalization of the aquaporin-2
water channel. Proc Natl Acad Sci U S A 104: 16696–16701, 2007
23. Lu HA, Sun TX, Matsuzaki T, Yi XH, Eswara J, Bouley R, McKee M,
Brown D: Heat shock protein 70 interacts with aquaporin-2 and reg-
ulates its trafficking. J Biol Chem 282: 28721–28732, 2007
24. Ward DM, Vaughn MB, Shiflett SL, White PL, Pollock AL, Hill J,
Schnegelberger R, Sundquist WI, Kaplan J: The role of LIP5 and
CHMP5 in multivesicular body formation and HIV-1 budding in mam-
malian cells. J Biol Chem 280: 10548–10555, 2005
25. Deen PMT, van Os CH: Epithelial aquaporins. Curr Opin Cell Biol 10:
435–442, 1998
26. Nielsen S, Frokiaer J, Marples D, Kwon TH, Agre P, Knepper MA:
Aquaporins in the kidney: From molecules to medicine. Physiol Rev
82: 205–244, 2002
27. Hasler U, Mordasini D, Bens M, Bianchi M, Cluzeaud F, Rousselot M,
Vandewalle A, Feraille E, Martin PY: Long-term regulation of aqua-
porin-2 expression in vasopressin-responsive renal collecting duct
principal cells. J Biol Chem 277: 10379–10386, 2002
28. Li Y, Shaw S, Kamsteeg EJ, Vandewalle A, Deen PM: Development of
lithium-induced nephrogenic diabetes insipidus is dissociated from
adenylyl cyclase activity. J Am Soc Nephrol 17: 1063–1072, 2006
29. Shiflett SL, Ward DM, Huynh D, Vaughn MB, Simmons JC, Kaplan J:
Characterization of Vta1p, a class E Vps protein in Saccharomyces
cerevisiae. J Biol Chem 279: 10982–10990, 2004
30. Shim S, Merrill SA, Hanson PI: Novel interactions of ESCRT-III with LIP5
and VPS4 and their implications for ESCRT-III disassembly. Mol Biol
Cell 19: 2661–2672, 2008
31. Azmi IF, Davies BA, Xiao J, Babst M, Xu Z, Katzmann DJ: ESCRT-III
family members stimulate Vps4 ATPase activity directly or via Vta1.
Dev Cell 14: 50–61, 2008
32. Xiao J, Xia H, Zhou J, Azmi IF, Davies BA, Katzmann DJ, Xu Z:
Structural basis of Vta1 function in the multivesicular body sorting
pathway. Dev Cell 14: 37–49, 2008
33. Azmi I, Davies B, Dimaano C, Payne J, Eckert D, Babst M, Katzmann
DJ: Recycling of ESCRTs by the AAA-ATPase Vps4 is regulated by a
conserved VSL region in Vta1. J Cell Biol 172: 705–717, 2006
34. Scott A, Gaspar J, Stuchell-Brereton MD, Alam SL, Skalicky JJ,
Sundquist WI: Structure and ESCRT-III protein interactions of the MIT
domain of human VPS4A. Proc Natl Acad Sci U S A 102: 13813–
13818, 2005
35. Babst M: A protein’s final ESCRT. Traffic 6: 2–9, 2005
36. Morita E, Sundquist WI: Retrovirus budding. Annu Rev Cell Dev Biol
20: 395–425, 2004
37. Pisitkun T, Shen RF, Knepper MA: Identification and proteomic pro-
filing of exosomes in human urine. Proc Natl Acad Sci U S A 101:
13368–13373, 2004
38. Nejsum LN, Zelenina M, Aperia A, Frokiaer J, Nielsen S: Bidirectional
regulation of AQP2 trafficking and recycling: Involvement of AQP2–
S256 phosphorylation. Am J Physiol Renal Physiol 288: F930–F938,
2005
39. Hoffert JD, Pisitkun T, Wang G, Shen RF, Knepper MA: Quantitative
phosphoproteomics of vasopressin-sensitive renal cells: regulation of
aquaporin-2 phosphorylation at two sites. Proc Natl Acad Sci U S A
103: 7159–7164, 2006
40. Tchernev VT, Mansfield TA, Giot L, Kumar AM, Nandabalan K, Li Y,
Mishra VS, Detter JC, Rothberg JM, Wallace MR, Southwick FS,
Kingsmore SF: The Chediak-Higashi protein interacts with SNARE
complex and signal transduction proteins. Mol Med 8: 56–64, 2002
BASIC RESEARCH www.jasn.org
1000 Journal of the American Society of Nephrology J Am Soc Nephrol 20: 990–1001, 2009
41. Faigle W, Raposo G, Tenza D, Pinet V, Vogt AB, Kropshofer H, Fischer
A, Saint-Basile G, Amigorena S: Deficient peptide loading and MHC
class II endosomal sorting in a human genetic immunodeficiency
disease: The Chediak-Higashi syndrome. J Cell Biol 141: 1121–1134,
1998
42. Shukla A, Hager H, Corydon TJ, Bean AJ, Dahl R, Vajda Z, Li H,
Hoffmann HJ, Nielsen S: SNAP-25-associated Hrs-2 protein colocal-
izes with AQP2 in rat kidney collecting duct principal cells. Am J
Physiol Renal Physiol 281: F546–F556, 2001
43. Girsch SJ, Peracchia C: Calmodulin interacts with a C-terminus pep-
tide from the lens membrane protein MIP26. Curr Eye Res 10: 839–
849, 1991
44. Bartel PL, Fields S: Analyzing protein-protein interactions using two-
hybrid system. Methods Enzymol 254: 241–263, 1995
45. Madrid R, Le Maout S, Barrault MB, Janvier K, Benichou S, Merot J:
Polarized trafficking and surface expression of the AQP4 water chan-
nel are coordinated by serial and regulated interactions with different
clathrin-adaptor complexes. EMBO J 20: 7008–7021, 2001
46. Gietz RD, Schiestl RH, Willems AR, Woods RA: Studies on the trans-
formation of intact yeast cells by the LiAc/SS-DNA/PEG procedure.
Yeast 11: 355–360, 1995
47. Dalton S, Treisman R: Characterization of SAP-1, a protein recruited by
serum response factor to the c-fos serum response element. Cell 68:
597–612, 1992
48. Hoffman CS, Winston F: A ten-minute DNA preparation from yeast
efficiently releases autonomous plasmids for transformation of Esch-
erichia coli. Gene 57: 267–272, 1987
49. Deen PMT, Verdijk MAJ, Knoers NVAM, Wieringa B, Monnens LAH,
van Os CH, van Oost BA: Requirement of human renal water channel
aquaporin-2 for vasopressin-dependent concentration of urine. Sci-
ence 264: 92–95, 1994
50. van Balkom BW, Van Raak M, Breton S, Pastor-Soler N, Bouley R, van
der SP, Brown D, Deen PM: Hypertonicity is involved in redirecting the
aquaporin-2 water channel into the basolateral, instead of the apical,
plasma membrane of renal epithelial cells. J Biol Chem 278: 1101–
1107, 2003
51. Karunagaran D, Tzahar E, Liu N, Wen D, Yarden Y: Neu differentiation
factor inhibits EGF binding: A model for trans-regulation within the
ErbB family of receptor tyrosine kinases. J Biol Chem 270: 9982–9990,
1995
52. van de Wetering M, Oving I, Muncan V, Pon Fong MT, Brantjes H, van
Leenen D, Holstege FC, Brummelkamp TR, Agami R, Clevers H:
Specific inhibition of gene expression using a stably integrated, in-
ducible small-interfering-RNA vector. EMBO Rep 4: 609–615, 2003
53. Seppen J, Rijnberg M, Cooreman MP, Oude Elferink RP: Lentiviral
vectors for efficient transduction of isolated primary quiescent hepa-
tocytes. J Hepatol 36: 459–465, 2002
54. Deen PMT, Nielsen S, Bindels RJM, van Os CH: Apical and basolateral
expression of aquaporin-1 in transfected MDCK and LLC-PK cells and
functional evaluation of their transcellular osmotic water permeabili-
ties. Pflugers Arch 433: 780–787, 1997
55. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, Naldini L:
A third-generation lentivirus vector with a conditional packaging sys-
tem. J Virol 72: 8463–8471, 1998
56. McLean IW, Nakane PK: Periodate-lysine-paraformaldehyde fixative:
A new fixation for immunoelectron microscopy. J Histochem Cyto-
chem 22: 1077–1083, 1974
57. Deen PMT, Van Balkom BWM, Savelkoul PJ, Kamsteeg EJ, Van Raak
M, Jennings ML, Muth TR, Rajendran V, Caplan MJ: Aquaporin-2:
COOH terminus is necessary but not sufficient for routing to the apical
membrane. Am J Physiol Renal Physiol 282: F330–F340, 2002
58. Deen PMT, van Aubel RA, van Lieburg AF, van Os CH: Urinary content
of aquaporin 1 and 2 in nephrogenic diabetes insipidus. J Am Soc
Nephrol 7: 836–841, 1996
59. Deen PMT, Croes H, van Aubel RA, Ginsel LA, van Os CH: Water
channels encoded by mutant aquaporin-2 genes in nephrogenic dia-
betes insipidus are impaired in their cellular routing. J Clin Invest 95:
2291–2296, 1995
60. Deen PMT, Rijss JPL, Mulders SM, Errington RJ, van Baal J, van Os CH:
Aquaporin-2 transfection of Madin-Darby canine kidney cells recon-
stitutes vasopressin-regulated transcellular osmotic water transport.
J Am Soc Nephrol 8: 1493–1501, 1997
Supplemental information for this article is available online at http://www.jasn.org/.
BASIC RESEARCHwww.jasn.org
J Am Soc Nephrol 20: 990–1001, 2009 LIP5 Directs AQP2 Degradation 1001
